These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. New developments in the use of gene therapy to treat Duchenne muscular dystrophy. Jarmin S; Kymalainen H; Popplewell L; Dickson G Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293 [TBL] [Abstract][Full Text] [Related]
29. Therapeutics for Duchenne muscular dystrophy: current approaches and future directions. Bogdanovich S; Perkins KJ; Krag TO; Khurana TS J Mol Med (Berl); 2004 Feb; 82(2):102-15. PubMed ID: 14673527 [TBL] [Abstract][Full Text] [Related]
30. Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy. Araki E; Nakamura K; Nakao K; Kameya S; Kobayashi O; Nonaka I; Kobayashi T; Katsuki M Biochem Biophys Res Commun; 1997 Sep; 238(2):492-7. PubMed ID: 9299538 [TBL] [Abstract][Full Text] [Related]
31. Gene-editing, immunological and iPSCs based therapeutics for muscular dystrophy. Singh S; Singh T; Kunja C; Dhoat NS; Dhania NK Eur J Pharmacol; 2021 Dec; 912():174568. PubMed ID: 34656607 [TBL] [Abstract][Full Text] [Related]
32. Relatively low proportion of dystrophin gene deletions in Israeli Duchenne and Becker muscular dystrophy patients. Shomrat R; Gluck E; Legum C; Shiloh Y Am J Med Genet; 1994 Feb; 49(4):369-73. PubMed ID: 8160727 [TBL] [Abstract][Full Text] [Related]
33. Detection of gene deletions by PCR analysis in a Malaysian patient with Duchenne muscular dystrophy. Lee MK; Manonmani V; Arahata K Med J Malaysia; 1993 Mar; 48(1):46-50. PubMed ID: 8341171 [TBL] [Abstract][Full Text] [Related]
34. Myoediting: Toward Prevention of Muscular Dystrophy by Therapeutic Genome Editing. Zhang Y; Long C; Bassel-Duby R; Olson EN Physiol Rev; 2018 Jul; 98(3):1205-1240. PubMed ID: 29717930 [TBL] [Abstract][Full Text] [Related]
36. Immunological detection of the dystrophin molecule with antibody directed against the synthetic peptide. Ohta M; Ohta K; Hara H; Itoh N; Itagaki Y; Nishitani H; Hayashi K Biochem Int; 1991 Dec; 25(6):1087-93. PubMed ID: 1810253 [TBL] [Abstract][Full Text] [Related]
37. Use of dystrophin genomic and cDNA probes for solving difficulties in carrier detection and prenatal diagnosis of Duchenne muscular dystrophy. Shomrat R; Driks N; Legum C; Shiloh Y Am J Med Genet; 1992 Feb; 42(3):281-7. PubMed ID: 1536162 [TBL] [Abstract][Full Text] [Related]
38. Current understanding of dystrophin-related muscular dystrophy and therapeutic challenges ahead. Zhou GQ; Xie HQ; Zhang SZ; Yang ZM Chin Med J (Engl); 2006 Aug; 119(16):1381-91. PubMed ID: 16934185 [TBL] [Abstract][Full Text] [Related]